



MASSACHUSETTS
GENERAL HOSPITAL

CANCER CENTER

Program

*The Henri and Belinda Termeer Center for Targeted Therapies
Presents a Roundtable Panel Discussion on*



Overcoming Obstacles to Development of Combination Targeted Therapies

5:30 pm

Welcome and Introductions

Daniel A. Haber, MD, PhD

Director, Mass General Cancer Center

Henri A. Termeer

Former Chairman, President and CEO, Genzyme Corporation

Panel Discussion

Overcoming Obstacles to Development of Combination Targeted Therapies

Moderator

Keith Flaherty, MD

Director, Henri and Belinda Termeer Center for Targeted Therapies, Mass General Cancer Center

Panelists

Marc Theoret, MD

Lead Medical Officer

Food and Drug Administration

Jeff Allen, PhD

Executive Director, Friends of Cancer Research

David Schenkein, MD

CEO, Agios Pharmaceuticals

Jeffrey Engelman, MD, PhD

*Director, Thoracic Oncology, Molecular Therapeutics
Scientific Director, Henri and Belinda Termeer Center for
Targeted Therapies, Mass General Cancer Center*

6:25 pm

Panel discussion with audience

7:30 pm

Cocktail reception

Hosts



Daniel A. Haber, MD, PhD

Dr. Haber is Director of the Mass General Cancer Center and the Isselbacher/Schwartz Professor of Oncology at Harvard Medical School. His laboratory focuses on cancer genetics and is broadly known for discoveries that have improved the treatment of cancers such as non-small cell lung cancer, breast cancer and Wilms tumor, as well as for innovation in cancer diagnostics.



Henri A. Termeer

Mr. Termeer served as Chairman, President and Chief Executive Officer of Genzyme Corporation for nearly three decades. Under his leadership, Genzyme grew from a modest entrepreneurial venture into one of the world's leading biotechnology companies. Mr. Termeer resigned from Genzyme in June 2011 following the acquisition of Genzyme by Sanofi. He is a member of the board at both Mass General Hospital and Partners HealthCare.

Panelists



Keith T. Flaherty, MD • moderator

Dr. Flaherty is Director of the Henri and Belinda Termeer Center for Targeted Therapies at the Mass General Cancer Center and Associate Professor of Medicine at Harvard Medical School. Dr. Flaherty's research and clinical focus is therapies for melanoma, with a particular expertise in targeted therapies.



David Schenkein, MD

Dr. Schenkein is a hematologist and CEO of Agios Pharmaceuticals. Prior to Agios, Dr. Schenkein was the SVP, clinical oncology, at Genentech. Prior to Genentech, he was the SVP of clinical research at Millennium Pharmaceuticals, overseeing the clinical development of Velcade. Dr. Schenkein spent 14 years as an attending physician at Tufts Medical Center in Boston, where he was the director of the Cancer Center.



Marc Theoret, MD

Dr. Theoret serves as Lead Medical Officer, Department of Health and Human Services, Food and Drug Administration (FDA) in the Center for Drug Evaluation and Research (CDER), Office of Medical Products and Tobacco (OMPT), Office of New Drug Quality Assessment (OND), Office of Hematology and Oncology Products (OHOP). He attended the Pennsylvania State University/College of Medicine, trained at the Beth Israel Deaconess Medical Center, Boston, before going to the National Institutes of Health in Bethesda, MD.



Jeffrey Engelman, MD, PhD

Dr. Engelman is the Director of Thoracic Oncology, the Director of Molecular Therapeutics and the Scientific Director for the Termeer Center for Targeted Therapies at the Mass General Cancer Center. Dr. Engelman has been instrumental in understanding sensitivity and resistance to targeted therapies in lung cancer. Dr. Engelman leads the translational research programs of the thoracic oncology team and the phase I program at the Mass General Cancer Center.



Jeff Allen, PhD

Jeff Allen, PhD serves as the Executive Director of Friends of Cancer Research (Friends), a think tank and advocacy organization in Washington, D.C. As a thought leader on many issues related to Food and Drug Administration, regulatory strategy and healthcare policy, he is regularly published in prestigious medical journals and policy publications, and has contributed his expertise to the legislative process on multiple occasions.

